公开(公告)号：EP2617702A2

公开(公告)日：2013-07-24

申请号：EP11816629.7

申请日：2011-08-11

申请人： Korea Institute of Oriental Medicine

发明人： KIM, Jin Sook ,  KIM, Young Sook ,  KIM, Jung Hyun ,  SHON, Eun Jin ,  KIM, Ki Mo ,  KIM, Chan-Sik ,  JUNG, Dong Ho ,  LEE, Yun Mi ,  JO, Kyu Hyung ,  KIM, Ohn Soon ,  YOO, Nam-Hee

IPC分类号： C07C43/23 ,  C07C33/26 ,  A61K36/73 ,  A23L1/29 ,  A61P3/10

CPC分类号： C07C43/23 ,  A21D2/24 ,  A23C2240/15 ,  A23L2/52 ,  A23L33/105 ,  A23V2002/00 ,  A61K36/73 ,  C07C41/38 ,  A23V2200/328 ,  A23V2250/156 ,  A23V2250/70

摘要： The present invention provides a novel biphenyl compound or pharmaceutically acceptable salts thereof, methods for preparing the same, and pharmaceutical compositions for preventing or treating diabetic complications containing the same as an active ingredient. Novel biphenyl compounds, according to the present invention, effectively suppress generation activity of advanced glycation end products, which cause diabetic complications and are a criterion for evaluating the effectiveness of a treating agent for diabetic complications, and show an excellent therapeutic effect on retina blood vessels, increased occludin, and decreased angiogenic growth factor in actual diabetic retinopathy induced retina. Thus, novel biphenyl compounds according to the present invention can be used effectively as an active ingredient in compositions for preventing or treating diabetic complications such as diabetic retinopathy.

摘要翻译： 本发明提供它们的新的联苯基化合物或其药学上可接受的盐，其制备方法，和药物组合物用于预防或治疗糖尿病并发症包含其作为上的活性成分的方法。 新的联苯基化合物，雅丁到本发明中，有效地抑制晚期糖化终产物，从而引起糖尿病并发症，并且是评估糖尿病并发症的处理剂的有效性的标准生成活性，和显示在视网膜血管优异的治疗效果 增加闭合蛋白，并诱导视网膜实际糖尿病性视网膜病变减少血管生成生长因子。 因此，新颖的联苯化合物gemäß到本发明可以在组合物被有效地用作活性成分的用于预防或治疗糖尿病并发症：如糖尿病性视网膜病。